Endocrine Abstracts

Aim: To estimate efficiency of long acting somatostatin analog (Oktreotid-Depot, Ltd ‘FarmSyntez’, Russia) in acromegaly treatment.Material and methods: Twenty-five patients with the confirmed acromegaly diagnosis, active phase, receiving Oktreotid-Depot therapy within 6–12 months in a single dose of 20–40 mg/month. Every three months dynamics of clinical signs, basal IGF-1 and GH levels and pituitary adenoma size were analyzed.<p...